DIFELIKEFALIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C36H53N7O6
Molecular Weight	679.8493
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N3CCC(N)(CC3)C(O)=O

InChI

InChIKey=FWMNVWWHGCHHJJ-SKKKGAJSSA-N

InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C36H53N7O6
Molecular Weight	679.8493
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/34674115 |https://pubmed.ncbi.nlm.nih.gov/34662080 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf

Difelikefalin (Korsuva™) is a synthetic peptide agonist of the kappa opioid receptor being developed by Cara Therapeutics for the treatment of pruritus. In August 2021, intravenous difelikefalin was approved in the USA for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis. Difelikefalin selectively acts on kappa opioid receptors in peripheral tissues, which contribute to pruritis and nociception. The activation of opioid receptors in peripheral neurons and keratinocytes reduces afferent (sensory) impulses towards the central nervous system, decreasing pain signals. Activating kappa opioid receptors on immune cells, including monocytes and T lymphocytes, decreases the release of pro-inflammatory chemicals such as prostaglandins.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://patents.google.com/patent/US7402564B1 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	Agonist 2752		0.16 nM [null]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pruritus 31 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf	Primary		Approved 8583	Korsuva Approved Use Treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis. Launch Date 2021

C_max

Value	Dose	Co-administered	Analyte	Population
61.9 ng/mL EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	5 μg/kg single, intravenous dose: 5 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
168.8 ng/mL EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	15 μg/kg single, intravenous dose: 15 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
94 ng × h/mL EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	5 μg/kg single, intravenous dose: 5 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
246 ng × h/mL EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	15 μg/kg single, intravenous dose: 15 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
31 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52	unknown, intravenous	DIFELIKEFALIN plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2 h EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	5 μg/kg single, intravenous dose: 5 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2 h EXPERIMENT https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	15 μg/kg single, intravenous dose: 15 μg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	DIFELIKEFALIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
73% REVIEW https://pubmed.ncbi.nlm.nih.gov/33190563/			DIFELIKEFALIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 ug/kg single, intravenous Highest studied dose Dose: 15 ug/kg Route: intravenous Route: single Dose: 15 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000OtherR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000OtherR.pdf	Disc. AE: Anxiety, Injection site phlebitis... AEs leading to discontinuation/dose reduction: Anxiety Injection site phlebitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000OtherR.pdf
0.5 ug/kg 3 times / week multiple, intravenous Recommended Dose: 0.5 ug/kg, 3 times / week Route: intravenous Route: multiple Dose: 0.5 ug/kg, 3 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	Disc. AE: Gastrointestinal disorders, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (1.3%) Nausea (0.4%) Dizziness (0.4%) Headache (0.4%) Anxiety (0.9%) Insomnia (0.9%) Mental status changes (0.9%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf
0.5 ug/kg 3 times / week multiple, intravenous Recommended\|Studied dose Dose: 0.5 ug/kg, 3 times / week Route: intravenous Route: multiple Dose: 0.5 ug/kg, 3 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	Disc. AE: Gastrointestinal disorders, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (0.5%) Nausea (0.5%) Dizziness (1.6%) Headache (0.5%) Psychiatric disorders (1.6%) Mental status changes (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1193 inhibitor 2438	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 UGT1A3 89 OCT2 779 OATP1B1 1079 UGT1A9 148 BCRP 910 UGT2B7 197 MATE1 415 CYP2C19 2057 CYP2B6 926 OAT1 725 P-gp 1741 OAT3 747 CYP2C8 1057 MATE2-K 77 OATP1B3 961 BSEP 550 MRP2 499 CYP3A 227 CYP1A2 2153 PEPT1 27	CYP2C8 810 CYP2C19 1119 CYP1A2 1197 BSEP 63 CYP3A 220 PEPT1 60 PEPT2 37 OCT3 92 OCT2 434 OAT2 125 OAT3 391 OATP1A2 67 OATP1B1 503 LAT1 2 ASBT 5 OAT1 395 OATP2B1 122 MRP2 252 OATP1B3 435 OCT1 393 OCTN1 55 OCTN2 59 P-gp 2052 BCRP 697 OSTalpha/beta 2 MATE1 182 MATE2-K 33	CYP1A2 832 CYP3A 142 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=60 Page: 51 \| 53 \| 60	no [Inhibition 10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=60 Page: 51 \| 53 \| 60	no [Inhibition 10 uM]
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=60 Page: 51 \| 53 \| 60	no [Inhibition 10 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=61 Page: 61.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
MATE2-K 77	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
MRP2 625	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=61 Page: 61.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
PEPT1 29	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=61 Page: 61.0	no
UGT1A3 99	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
UGT1A9 155	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
UGT2B7 210	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no

Drug as victim

Target	Modality	Activity
ASBT 5	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
BSEP 63	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
LAT1 2	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
MATE2-K 33	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
MRP2 252	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OAT2 125	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OATP1A2 67	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OATP2B1 122	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=51 Page: 51 \| 53	no
OCT3 92	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OCTN1 55	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OCTN2 59	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
OSTalpha/beta 2	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
PEPT1 60	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no
PEPT2 37	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52 Page: 52 \| 53	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=36 Page: 33 \| 36

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dosage is 0.5 mcg/kg. Administer by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD treatment. Do not mix or dilute KORSUVA prior to administration. Administer within 60 minutes of syringe preparation.

Route of Administration: Intravenous

In Vitro Use Guide

Difelikefalin activates KOR in HEK293 cells expressing the human receptor (EC50 = 0.16 nM in a transactivation assay) and inhibits forskolin-induced cAMP production in R1.G1 mouse thyoma cells (EC50 = 0.048 nM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:35:57 GMT 2025` Edited by `admin` on `Mon Mar 31 23:35:57 GMT 2025`
Record UNII	NA1U919MRO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

difelikefalin [INN]

Preferred Name

English

DIFELIKEFALIN

Official Name

English

CR-845

Code

English

FE202845

Code

English

DIFELIKEFALIN [USAN]

Common Name

English

MR-13A9

Code

English

Difelikefalin [WHO-DD]

Common Name

English

FE-202845

Code

English

DIFELIKEFALIN ACETATE [JAN]

Common Name

English

MR13A9

Code

English

4-AMINO-1-(D-PHENYLALANYL-D-PHENYLALANYL-D-LEUCYL-D-LYSYL)PIPERIDINE-4-CARBOXYLIC ACID

Systematic Name

English

4-PIPERIDINECARBOXYLIC ACID, N1-(D-PHENYLALANYL-D-PHENYLALANYL-D-LEUCYL-D-LYSYL)-4-AMINO-

Code

English

CR845

Code

English

Code System Code Type Description

EPA CompTox

DTXSID401032896